The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
- 15 September 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (6), 2041-2048
- https://doi.org/10.1182/blood-2007-04-082495
Abstract
The heparan sulfate proteoglycan syndecan-1 is expressed by myeloma cells and shed into the myeloma microenvironment. High levels of shed syndecan-1 in myeloma patient sera correlate with poor prognosis and studies in animal models indicate that shed syndecan-1 is a potent stimulator of myeloma tumor growth and metastasis. Overexpression of extracellular endosulfatases, enzymes which remove 6-O sulfate groups from heparan sulfate chains, diminishes myeloma tumor growth in vivo. Together, these findings identify syndecan-1 as a potential target for myeloma therapy. Here, 3 different strategies were tested in animal models of myeloma with the following results: (1) treatment with bacterial heparinase III, an enzyme that degrades heparan sulfate chains, dramatically inhibited the growth of primary tumors in the human severe combined immunodeficient (SCID-hu) model of myeloma; (2) treatment with an inhibitor of human heparanase, an enzyme that synergizes with syndecan-1 in promoting myeloma progression, blocked the growth of myeloma in vivo; and (3) knockdown of syndecan-1 expression by RNAi diminished and delayed myeloma tumor development in vivo. These results confirm the importance of syndecan-1 in myeloma pathobiology and provide strong evidence that disruption of the normal function or amount of syndecan-1 or its heparan sulfate chains is a valid therapeutic approach for this cancer.Keywords
This publication has 60 references indexed in Scilit:
- Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaBlood, 2007
- The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2006
- Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple MyelomaClinical Cancer Research, 2006
- Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myelomaOncogene, 2006
- Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fatBone, 2006
- Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapiesJournal of Cellular Biochemistry, 2005
- The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cellsThe Journal of cell biology, 2004
- QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signalingThe Journal of cell biology, 2003
- Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo.JCI Insight, 1998
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994